Carlo J. Di Fonzo PhD

Carlo J. Di Fonzo leads drug development and regulatory affairs at Nektar with oversight responsibilities for regulatory affairs, GCP/GLP compliance and toxicology. Dr. Di Fonzo's experience includes over 25 years in regulatory affairs and safety roles in the pharmaceutical and biotechnology industry. During his career, Dr. Di Fonzo has been part of several teams that helped bring new medicines to patients, including Lipitor, Neurontin, Accupril, Xigris, Forteo, Alimta, Gemzar, Zyprexa, Strattera, Cialis and Movantik. Prior to joining Nektar in 2006, Dr. Di Fonzo led regulatory affairs and quality compliance at Eli Lilly Canada, where he was also responsible for patent-listing strategies and product safety functions. Prior to joining Eli Lilly in November 2000, he worked at Warner-Lambert/Parke-Davis Canada, where he was had oversight of toxicology and safety studies as well as regulatory affairs.

Dr. Di Fonzo received his undergraduate degree in biologic sciences, his master's degree in clinical biochemistry and his Ph.D. in clinical biochemistry and toxicology from the University of Toronto, Canada.